A culturomics approach has enabled the isolation of \>295 new bacterial species from the human gut [@bib1]. Here, using culture conditions containing a high salt concentration [@bib2], we isolated strain S35^T^ from an extremely saline soil sample collected from the dry lake of Ank el Djamel in Algeria. This strain could not be identified by our systematic matrix-assisted laser desorption--ionization time-of-flight mass spectrometry (MALDI-TOF-MS) screening (<http://mediterranee-infection.com/article.php?laref=256&titre=urms-database>) on a Microflex spectrometer (Bruker Daltonics, Bremen, Germany) [@bib3].

Strain S35^T^ was isolated after 14 days of incubation at 30°C on International Streptomyces Project 4 medium (ISP4) (Becton Dickinson, Le Pont-de-Claix, France) modified by the addition of 50 g/L of NaCl and with pH adjusted to 8. Then, the growing colonies were sub-cultured on 5% sheep\'s blood-enriched Columbia agar (bioMérieux, Marcy l'Etoile, France) for 7 days in an aerobic atmosphere at 37°C.

Strain S35^T^ is a Gram-positive, filamentous-shape, ranging from 0.4 to 0.6 μm in diameter. The colonies obtained after 7 days of incubation appear opaque, brown with a wrinkled surface with a mean diameter of 2 mm. Strain S35^T^ exhibited catalase but not oxidase activity. This strain is mesophilic and strictly aerobic, growing optimally at 37°C and pH 7.5.

Identification based on 16S rDNA demonstrates that strain S35^T^ exhibits 97.26% sequence identity with *Streptomyces albus* ATCC 25426 (GenBank Accession number DQ026669.1), its most closely related species with standing in nomenclature [@bib4] ([Fig. 1](#fig1){ref-type="fig"}). This value is under the threshold of 98.7% separating new species established by Stackebrandt and Ebers [@bib5]. Consequently, we propose the creation of "*Streptomyces massilialgeriensis*" sp. nov., a new bacterial species belonging to the *Streptomyces* genus. Strain S35^T^ is the type strain of "*Streptomyces massilialgeriensis*" sp. nov. (ma.sil.io.al.ge.ri.en\'sis. L. gen. masc. n. *massilioalgeriensis*, a combination of *massili* for Massilia, the Roman name of Marseille where the type strain S35^T^ was identified and sequenced, and *algeriensis*, for Algeria, the country in North Africa, where the strain was isolated).Fig. 1Phylogenetic tree showing the position of "*Streptomyces massilialgeriensis*" strain S35^T^ relative to other phylogenetically close neighbours. The 16S rRNA gene sequences were aligned using CLUSTAL W, and phylogenetic inferences were obtained using the maximum-likelihood method within the MEGA software. Numbers at the nodes are percentages of bootstrap values obtained by repeating the analysis 500 times to generate a majority consensus tree. Only bootstrap scores of at least 95 were retained. The scale bar indicates a 0.005% nucleotide sequence divergence.

Actinobacteria are considered as providers of molecules of medical interest with antitumour, antiviral and antiparasitic activities. In particular, species belonging to the genus *Streptomyces* are producing the majority of the antibiotics used in human therapy. It has been estimated that out of 16 500 known antibiotics, 8700 are produced by Actinobacteria, including 6550 by *Streptomyces* species [@bib6]. These bacteria actually have a large number of "hidden" or "cryptic" metabolites. If we could induce the production of these metabolites, it would be possible to obtain several new molecules of therapeutic interest.

**MALDI-TOF spectrum** The MALDI-TOF-MS spectrum of "*Streptomyces massilialgeriensis*" is available in: <http://www.mediterranee-infection.com/article.php?laref=256&titre=urms-database>.

**Nucleotide sequences accession numbers** The 16S rRNA gene sequence of "*Streptomyces massilialgeriensis*" was deposited in GenBank under Accession number: LT838406.

**Deposit in a culture collection** The strain S35^T^ was deposited in the Collection de Souches de l'Unité des Rickettsies (CSUR) under number P3927.
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